Navigation Links
Hope For Patients With Macular Degeneration From Manmade Protein

A new man made protein has been shown to reduce potentially blinding blood vessel growth in the cornea following an eye injury //or even surgery by over 50 percent, according to researchers.

'We believe eventually we'll be able to use this protein to help patients in many situations where blood vessel formation is detrimental, including cancer, diabetic retinopathy and macular degeneration,' says Dr. Balamurali K. Ambati, corneal specialist at the Medical College of Georgia and Augusta Veterans Affairs Medical Center. Dr. Ambati is corresponding author of the study published in the November issue of Investigative Ophthalmology & Visual Science.

The body can produce new blood vessels to promote healing after trauma, such as a corneal transplant, a significant corneal scratch from a contact lens or retinal oxygen deprivation caused by diabetes or aging. This natural response, called angiogenesis, becomes detrimental when new growth obstructs vision or when a tumor pirates the process to survive.

In an animal model, researchers used the protein they developed to reverse obstructive growth as long as one month after injury, says Dr. Ambati. That's a very long time after injury in a mouse’s lifetime, indicating even well-established blood vessels are susceptible to intraceptor-mediated regression, he says.

This intraceptor traps vascular endothelial growth factor, or VEGF, inside the protein making machinery of a cell. It's made with a portion of a VEGF receptor called sflt-1, a free-floating receptor recently shown to help keep the cornea clear by taking up and effectively neutralizing VEGF. Although other molecules have an anti-angiogenic effect, sflt-1 was the only one they found that spurs corneal blood vessels when blocked. The work, published in October in Nature, was led by teams at MCG and the University of Kentucky.

'Now we have designed a novel recombinant molecule where we take a subunit of sflt-1 and c ouple it with a four-amino-acid peptide tail,' he says. 'The tail essentially handcuffs the manmade molecule within the protein-making machinery of the cell so that it stays there and anything that binds with it, namely VEGF, stays there too. So it's a very specific way of down-regulating a target protein.'

In May 2005, Dr. Ambati and his colleagues published work in Investigative Ophthalmology & Visual Science showing the intraceptor helped reduce blood vessel development in the test tube and animal models for corneal injury and melanoma.

'Now we are talking about making them go away,' says Dr. Ambati. While the work is still in the laboratory, it provides further evidence of the intraceptor’s potential clinical application, he says.

The work shows the intraceptor prompts regression of blood vessels by inducing programmed cell death, or apoptosis, in the vascular endothelial cells that line the vessels.

'The biology of all this is showing this molecule interrupts the proper folding of proteins involved in existing blood vessels, which makes them die. It's a nice result,' says Dr. Ambati.

Some existing anti-angiogenesis treatments target VEGF outside cells. 'It is important to bind it within cells because certain cells, such as cancer and blood vessel cells, have the capability to produce their own VEGF and their own receptors,' Dr. Ambati says. 'Imagine trying to block from the outside a factory that has everything it needs inside. You have to throw a monkey wrench inside the factory and that is what we managed to do.'

For the study, the manmade protein was injected directly into the cornea with a microneedle. 'Ideally we would like to develop a topical eye drop with a long-term delivery system,' says Dr. Ambati.

His research team is pursuing its work of the intraceptor's potential role in destroying blood vessels that help sustain cancers. They also are looking at a biodegradable pol ymer cage so they can encapsulate the intraceptor, tag it with a homing device for target cells and deliver it 'like a missile carrying a payload' into the desired cells where it will slowly release the intraceptor, he says.

Co-authors include Dr. Nirbhai Singh, MCG postdoctoral fellow; Pooja D. Jani and Shivan Amin, MCG medical students; and Tushar Suthar, a medical student at New York Medical College in Valhalla.

The research was funded by the Knights-Templar Eye Foundation, Fight For Sight Grant-in-Aid and the Association for Research in Vision and Ophthalmology/Alcon Postdoctoral Fellowship.


Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:

(Date:11/30/2015)... Minneapolis, MN (PRWEB) , ... December 01, 2015 ... ... Nationwide® is the latest carrier to offer individual vision insurance plans on ... with the unique ability to rate and review products, allowing consumers to compare, ...
(Date:11/30/2015)... Louis, MO (PRWEB) , ... November 30, 2015 , ... ... and exclusion criteria set forth in the MOMS (Management of Myelomeningocele Study) trial. One ... for Disease Control and Prevention), a BMI of 18.5 to 24.9 is considered normal, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Stress, anxiety, illness, infection or ... worry about possible tumors? , Heather Spader, MD, a new pediatric neurosurgeon at Joe ... some signs might point to tumors. , “Bad headaches that don’t go ...
(Date:11/30/2015)... ... 2015 , ... Thermi™, a world leader in thermistor-regulated energy ... temperature controlled radiofrequency platform has received CE marking and may now be sold ... as a clinical endpoint. The technology has been available in the United ...
(Date:11/30/2015)... ... 2015 , ... MOSI recently added two state-of-the-art augmented reality (AR) experiences from ... to their collection of interactive exhibits within the Kids In Charge! building. In collaboration ... to get closer than ever to a range of animals as they drink, sleep ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015 MEDTEC Japon 2016, ... d,Asie portant sur la conception de ... se tiendra à Tokyo ... avril 2016. ... - Logo - ...
(Date:11/30/2015)... TOKYO , Nov. 30, 2015 MEDTEC Japan 2016, ... and Manufacturing industry, is to be held in Tokyo from 20 th  - 22 ... --> -->   --> ...   the United States . With the aging population ... markets continuing to grow steadily. --> the United States ...
(Date:11/30/2015)... -- QT Vascular Ltd., together with its subsidiaries (the "Company" ... Medical LLC and Quattro Vascular Pte. Ltd., collectively the ... and distribution of advanced therapeutic solutions for the minimally ... that a three-judge panel of the United ... Circuit ("Federal Circuit") has unanimously granted the Group and ...
Breaking Medicine Technology: